Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0V1FF
|
||||
| Former ID |
DIB012482
|
||||
| Drug Name |
Davunetide intranasal spray
|
||||
| Synonyms |
Davunetide; NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics
|
||||
| Indication | Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10:F01-F07, F04, F05, R41.3] | Phase 3 | [531616] | ||
| Company |
Allon Therapeutics Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
N1(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2N(<br />C(=O)[C@@H](NC(=O)[C@H](CC(=O)N)N)C)CCC2)C(C)C)CO)[C@H]<br />(CC)C)[C@H](C(=O)N[C@H](C(=O)O)CCC(=O)N)CCC1
|
||||
| Target and Pathway | |||||
| Target(s) | Microtubule-associated protein tau | Target Info | Modulator | [531616] | |
| KEGG Pathway | MAPK signaling pathway | ||||
| Alzheimer's disease | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| EGFR1 Signaling Pathway | |||||
| Pathway Interaction Database | LPA receptor mediated events | ||||
| Reelin signaling pathway | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.